Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.
Pineda JA, Rivero-Juárez A, de Los Santos I, Collado A, Merino D, Morano-Amado LE, Ríos MJ, Pérez-Pérez M, Téllez F, Palacios R, Pérez AB, Mancebo M, Rivero A, Macías J. Pineda JA, et al. HIV Clin Trials. 2018 Feb;19(1):23-30. doi: 10.1080/15284336.2018.1436637. Epub 2018 Feb 15. HIV Clin Trials. 2018. PMID: 29447085 Clinical Trial.
Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.
Merchante N, Rivero-Juárez A, Téllez F, Merino D, Ríos-Villegas MJ, Villalobos M, Omar M, Rincón P, Rivero A, Pérez-Pérez M, Raffo M, López-Montesinos I, Palacios R, Gómez-Vidal MA, Macías J, Pineda JA; Members of the HEPAVIR-Cirrhosis Study Group. Merchante N, et al. J Antimicrob Chemother. 2018 Sep 1;73(9):2435-2443. doi: 10.1093/jac/dky234. J Antimicrob Chemother. 2018. PMID: 29982683 Free article.
Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
Macías J, Morano LE, Téllez F, Granados R, Rivero-Juárez A, Palacios R, Ríos M, Merino D, Pérez-Pérez M, Collado A, Figueruela B, Morano A, Freyre-Carrillo C, Martín JM, Rivero A, García F, Pineda JA; HEPAVIR group from the Sociedad Andaluza de Enfermedades Infecciosas (SAEI) and the GEHEP group from the Sociedad Española de Enfermedades Infecciosas y Microbiología (SEIMC). Macías J, et al. J Hepatol. 2019 Jul;71(1):45-51. doi: 10.1016/j.jhep.2019.02.018. Epub 2019 Mar 8. J Hepatol. 2019. PMID: 30853642
Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy.
Macías J, Márquez M, Téllez F, Merino D, Jiménez-Aguilar P, López-Cortés LF, Ortega E, von Wichmann MA, Rivero A, Mancebo M, Santos J, Pérez-Pérez M, Suárez-Lozano I, Romero-Palacios A, Torres-Cornejo A, Pineda JA. Macías J, et al. Clin Infect Dis. 2013 Nov;57(10):1401-8. doi: 10.1093/cid/cit537. Epub 2013 Aug 14. Clin Infect Dis. 2013. PMID: 23946224
Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term.
Macías J, Mancebo M, Márquez M, Merino D, Téllez F, Rivero A, von Wichmann MA, López-Cortés LF, Merchante N, Santos J, Raffo M, Pérez-Pérez M, Camacho Á, Iribarren JA, Pineda JA. Macías J, et al. Hepatology. 2015 May;61(5):1503-11. doi: 10.1002/hep.27674. Epub 2015 Mar 20. Hepatology. 2015. PMID: 25545020
Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis.
Merchante N, Téllez F, Rivero-Juárez A, Ríos-Villegas MJ, Merino D, Márquez-Solero M, Omar M, Recio E, Pérez-Pérez M, Camacho Á, Macías-Dorado S, Macías J, Lorenzo-Moncada S, Rivero A, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Merchante N, et al. BMC Infect Dis. 2015 Dec 7;15:557. doi: 10.1186/s12879-015-1291-3. BMC Infect Dis. 2015. PMID: 26643257 Free PMC article.
Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Merchante N, Rivero-Juárez A, Téllez F, Merino D, José Ríos-Villegas M, Márquez-Solero M, Omar M, Macías J, Camacho A, Pérez-Pérez M, Gómez-Mateos J, Rivero A, Antonio Pineda J; Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Merchante N, et al. Hepatology. 2012 Jul;56(1):228-38. doi: 10.1002/hep.25616. Epub 2012 Jun 6. Hepatology. 2012. PMID: 22278746
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
Macías J, Mancebo M, Merino D, Téllez F, Montes-Ramírez ML, Pulido F, Rivero-Juárez A, Raffo M, Pérez-Pérez M, Merchante N, Cotarelo M, Pineda JA; Spanish AIDS Research Network-HEP09 Study Group. Macías J, et al. Clin Infect Dis. 2017 Sep 15;65(6):1012-1019. doi: 10.1093/cid/cix467. Clin Infect Dis. 2017. PMID: 28903510 Free article. Clinical Trial.
Development of a luminescence-based method for measuring West Nile Virus MTase activity and its application to screen for antivirals.
Álvarez-Mínguez A, Del Río N, Belén-Blázquez A, Casanova E, Orduña JM, Camarero P, Hurtado-Marcos C, Del Águila C, Pérez-Pérez MJ, Martín-Acebes MA, Agudo R. Álvarez-Mínguez A, et al. Among authors: perez perez mj. Curr Res Microb Sci. 2024 Oct 2;7:100282. doi: 10.1016/j.crmicr.2024.100282. eCollection 2024. Curr Res Microb Sci. 2024. PMID: 39445035 Free PMC article.
287 results